0001209191-20-036808.txt : 20200615
0001209191-20-036808.hdr.sgml : 20200615
20200615194028
ACCESSION NUMBER: 0001209191-20-036808
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200615
FILED AS OF DATE: 20200615
DATE AS OF CHANGE: 20200615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nassif David W.
CENTRAL INDEX KEY: 0001636975
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 20964618
MAIL ADDRESS:
STREET 1: C/O STEADYMED THERAPEUTICS, INC.
STREET 2: 2410 CAMINO RAMON
CITY: SAN RAMON
STATE: CA
ZIP: 94583
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axovant Gene Therapies Ltd.
CENTRAL INDEX KEY: 0001636050
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981333697
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 11-12 ST. JAMES'S SQUARE
STREET 2: SUITE 1, 3RD FLOOR
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
BUSINESS PHONE: 44 203 318 9708
MAIL ADDRESS:
STREET 1: 11 TIMES SQUARE
STREET 2: 33RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences Ltd.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences, Inc.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Roivant Neurosciences Ltd.
DATE OF NAME CHANGE: 20150309
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-15
0
0001636050
Axovant Gene Therapies Ltd.
AXGT
0001636975
Nassif David W.
C/O AXOVANT GENE THERAPIES LTD.
11 TIMES SQUARE, 33RD FLOOR
NEW YORK
NY
10036
0
1
0
0
Principal Financial Officer
Common Shares
2020-06-11
4
A
0
15060
0.00
A
24210
D
Common Shares
2020-06-11
4
F
0
5266
3.25
D
18944
D
Restricted Stock Units
2020-06-12
4
D
0
15060
0.00
D
Common Shares
15060
15060
D
Balance includes 9,150 shares of Common Stock owned by the reporting person prior to his appointment as a Section 16 officer but was not previously reported.
Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
Each restricted stock unit represents the right to receive one share of the Issuer's common stock. 50% of the common shares underlying the restricted stock units vested on January 31, 2020 but settlement of such portion of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.
/s/ Alison Haggerty, Attorney-In-Fact
2020-06-15